Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Large scale processes for producing high purity samples of biologically active molecules of interest from bacterial cells are disclosed. The methods comprise the steps of producing a lysate solution by contacting a cell suspension of said plurality of cells with lysis solution; neutralizing said lysate solution with a neutralizing solution to produce a dispersion that comprises neutralized lysate solution and debris; filtering the dispersion through at least one filter; performing ion exchange separation on said neutralized lysate solution to produce an ion exchange eluate; and performing hydrophobic interaction separation on said ion exchange eluate to produce a hydrophobic interaction solution. Further, provided are compositions comprising large scale amounts of plasmid DNA produced by the disclosed large scale processes.

Abstract: Disclosed are a novel Akkermansia muciniphila EB-AMDK27 strain having the effect of preventing or treating inflammatory disease or metabolic disease, and a pharmaceutical composition effective for preventing or treating inflammatory disease or metabolic disease, which contains the strain, a culture thereof, or a dried product thereof. While traditional probiotics generally have insufficient therapeutic effects on inflammatory or metabolic diseases, the disclosed next generation probiotic strain has an excellent effect on the prevention or treatment of inflammatory disease and/or metabolic disease so that it may be used as a new prophylactic and therapeutic tool.

Abstract: The present invention provides cell-free systems comprising: (i) a transcription compartment; (ii) a barrier; and (iii) a translation compartment, methods for producing proteins and performing post-translational modifications thereon using such systems, and kits comprising such systems.

Abstract: Disclosed is a manufacturing method for a bio-sensor. The present manufacturing method comprise the steps of: preparing an acidic solution comprising an enzyme and a molecule containing a catechol group; an immersing electrodes in the acidic solution and applying a voltage to the electrodes, thereby attaching a structure, which is generated by a reaction of the enzyme and the molecule containing a catechol group, to the electrodes.

Abstract: Provided herein are methods of culturing a microorganism. The methods include providing a container comprising one or more microorganisms in a medium, which has a first carbon to nitrogen ratio; culturing the microorganisms until the culture reaches a threshold indicator; harvesting a portion of the culture while maintaining the majority of the culture in the container; and adding fresh medium comprising a second carbon to nitrogen ratio to the container with the majority of the culture comprising the microorganisms.

Abstract: The present invention relates to the effect of plasminogen in the treatment and/or elimination of angiocardiopathy, especially angiocardiopathy caused by diabetes mellitus, thereby providing a new strategy for treating different kinds of angiocardiopathy, especially angiocardiopathy and its related disorders caused by diabetes mellitus.

Abstract: The invention concerns a bioelectrode and a device comprising same, for detecting or oxidising glucose. The bioelectrode of the invention comprises a layer of carbon nano tubes to which aromatic molecules are bonded, and FAD-GDH enzymes being adsorbed on the aromatic molecules. The invention applies to the field of biosensors and biofuel cells in particular.

Abstract: A preparation containing the mycoparasitic microorganism Pythium oligandrum for the treatment of dermatophytoses and yeast infections on the skin and mucous membranes obtained from a dry mixture containing 0.1 to 99.9% weight mycoparasitic microorganism Pythium oligandrum and 0.1 to 99.9% auxiliary substances, containing at least one component from a group comprising adsorbent, buffer, moisturizer, deodorant and aroma. This preparation contains 1 to 10×106, with preference of 10 to 50, viable cells of the Pythium oligandrum microorganism per 1 ml of aqueous suspension at the site of applying the preparation, whereby the viable cells of the Pythium oligandrum microorganism comprise dormant oospores, encysted zoospores and viable coenocytic mycelium. Different application methods of using the preparation are claimed. Exemplary embodiments show the viability of cells using genetic tests and practical tests conducted under the supervision of dermatologists, stomatologists and veterinarians.

Abstract: A process for the preparation of bio-based malonic acid and crystalline calcium malonate is provided. The calcium malonate is highly pure and provides a source of malonic acid made from a renewable carbon source rather than existing processes which rely on the use of petroleum-based products. The calcium malonate provides an improved source of malonic acid, which is important to many industrial processes.

Abstract: The inventions described herein relate generally to the use of compositions to increase output of acetate and lactate while reducing pH and the levels of pathogenic bacteria and inflammation in the gut of a nursing infant mammal including humans. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal.

Abstract: The present invention relates to a method for restoring a balance between glucagon and insulin to normal, comprising administering an effective amount of plasminogen to a subject; furthermore, the present invention relates to a medicament for restoring a balance between glucagon and insulin to normal.

Abstract: A process for the continuous production of lactic acid (a first fermentation product) and of a second fermentation product selected from the group consisting of alcohols and biogas, may include starting from the milling, necessarily carried out under dry conditions, of cereals and more particularly of corn. In the context of this process, a main flow and a flow of wastes which are difficult to ferment are recovered from the milling. These two flows are treated separately but simultaneously so as to produce, by fermentation, on the one hand, lactic acid and, on the other hand, an alcohol and/or biogas.

Abstract: This disclosure relates to treating a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-?1) and/or transforming growth factor ? 2 (TGF-?2), connective tissue growth factor (CTGF), and a pharmaceutically acceptable excipient or a secondary agent.

Abstract: The invention relates to methods and instruments for determining the resistances of microbes to antibiotics, in particular those microbes which produce beta-lactamases. The method determines the resistance of the microbes in less than an hour by incubating a tiny quantity of the microbes on a mass spectrometric sample support plate after they have been combined with a dosed quantity of a suitable antibiotic, for example the beta-lactam antibiotic imipenem, and by direct mass spectrometric measurement of the breakdown of the antibiotic by the microbial enzymes.

Abstract: A method of preparing a bacterial composition is disclosed. The method comprises: (a) in vitro co-culturing beneficial bacteria with biofilm-producing bacteria in a growth substrate under conditions that generate a biofilm which comprises the beneficial bacteria and the non-pathogenic bacteria; and (b) isolating the biofilm from the growth substrate.

Abstract: A method for manufacturing carboxylic acid that includes the following steps is provided. First, subjecting an aqueous mixture, including carboxylic acid and at least 5 wt. % dissolved magnesium chloride, to a forward extraction step using a first organic liquid, including an organic solvent, the organic solvent being selected from the group of C5+ ketones, thereby obtaining an organic carboxylic acid solution and an aqueous waste liquid including magnesium chloride. Second, subjecting the organic carboxylic acid solution to a back extraction step wherein the carboxylic acid is extracted from the organic carboxylic acid solution into an aqueous liquid, thereby obtaining an aqueous carboxylic acid solution and a second organic liquid. Third, subjecting the aqueous waste liquid including magnesium chloride derived from the forward extraction to a thermal decomposition step at a temperature of at least 300° C., thereby decomposing the magnesium chloride to magnesium oxide and HCl.

Abstract: The present invention relates to the co-production and isolation of mycoprotein and ethanol from carbohydrate feedstock material (e.g cereals). The present invention also provides a fermentation system for the co-production of mycoprotein from a carbohydrate feedstock material.

Abstract: The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.

Abstract: A method produces xylo-oligosaccharides from a biomass containing xylan and cellulose, which method is convenient and has a high yield of xylo-oligosaccharides because of inhibition of degradation of xylo-oligosaccharides into xylose. In the method of producing xylo-oligosaccharides, a biomass containing xylan and cellulose is hydrolyzed with a cellulase composition having at least activities of xylanase, cellobiohydrolase and ?-glucosidase and substantially free of ?-xylosidase activity during hydrolysis.